Innate Pharma Files 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: Jun 17, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Jun 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, reporting
TL;DR
Innate Pharma filed a routine 6-K, nothing major to see here.
AI Summary
Innate Pharma SA filed a Form 6-K on June 17, 2025, reporting a press release dated the same day. The filing does not contain specific financial figures or operational details beyond the standard reporting requirements for a foreign private issuer.
Why It Matters
This filing indicates Innate Pharma is meeting its SEC reporting obligations as a foreign private issuer, which is standard procedure for companies with securities traded in the US.
Risk Assessment
Risk Level: low — This is a standard SEC filing for a foreign private issuer and does not contain new material information or significant financial events.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- June 17, 2025 (date) — Filing Date
- 001-39084 (other) — Commission File Number
FAQ
What type of report is Innate Pharma filing?
Innate Pharma is filing a Form 6-K report.
What is the filing date of this report?
The filing date is Monday, June 17, 2025.
What is the Commission File Number for Innate Pharma?
The Commission File Number is 001-39084.
Does Innate Pharma file annual reports under Form 20-F?
Yes, Innate Pharma indicates it files annual reports under Form 20-F.
What exhibit is included with this 6-K filing?
Exhibit 99.1, a Press Release dated June 17, 2025, is included with this filing.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 17, 2025 regarding Innate Pharma SA (IPHYF).